Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure (Dig&Iva)
Cardiac Failure
About this trial
This is an interventional treatment trial for Cardiac Failure focused on measuring Digoxin, Ivabradine, with atrial fibrillation.
Eligibility Criteria
Inclusion Criteria:
All patients had heart failure NYHA (New York Heart Association) class III. All had chronic and stable coronary artery disease which had been treated with percutaneous dilatation and stenting, and/or aortocoronary bypass. The pathology had induced a permanent AF and heart failure with left ventricular diastolic dysfunction and preserved systolic function. Preserved systolic function was defined by a LVEF (left ventricular ejection fraction) ≥52%. Left ventricular diastolic dysfunction was defined by a e/e1 ratio > 15 (septal spectral tissue-Doppler).
Exclusion Criteria:
Unstable myocardial ischemia, reduced systolic cardiac function (LVEF<52%), diabetes mellitus requiring insulin, moderate or severe renal or hepatic dysfunction, or technically insufficient echocardiography.
Sites / Locations
- Cardiology office
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Ivabradine
Digoxin
Ivabradine, 7,5 mg b.id. by mouth for 14-16 weeks.
Digoxin 0.125 mg once a day, 5 times per week, for 12-14 weeks by mouth.